ABUS
Arbutus Biopharma Corp
NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY
$4.32
+0.70% today
Updated 2026-10-28
Market cap
$646.82M
P/E ratio
5.34
P/S ratio
3.56x
EPS (TTM)
$0.79
Dividend yield
—
52W range
$4 – $5
Volume
5.9M
Arbutus Biopharma Corp (ABUS) Insider transactions
Net insider activity
Net buying (3,174,406 shares)
Buy transactions
65
Sell transactions
15
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-10-01 | SAWHNEY, ROGER | Director | Sale | 17,142 | $5.00 | $85710.00 |
| 2026-10-01 | ROIVANT, SCIENCES LTD. | Director, 10% Owner | Sale | 8,967,383 | $5.00 | $44.84M |
| 2026-10-01 | NGUYEN, TUAN | Chief Financial Officer | Sale | 48,081 | $5.00 | $240405.00 |
| 2026-10-01 | BEARDSLEY, ROBERT A | Director | Sale | 17,948 | $5.00 | $89740.00 |
| 2026-10-01 | ANDROSKI, LINDSAY | Director, President and CEO | Sale | 24,655 | $5.00 | $123275.00 |
| 2026-09-18 | SAWHNEY, ROGER | Director | M | 78,800 | — | — |
| 2026-09-18 | SAWHNEY, ROGER | Director | M | 52,533 | — | — |
| 2026-09-18 | SAWHNEY, ROGER | Director | F | 100,508 | $5.07 | $509575.56 |
| 2026-09-18 | SAWHNEY, ROGER | Director | M | 78,800 | $4.24 | $334112.00 |
| 2026-09-18 | SAWHNEY, ROGER | Director | M | 52,533 | $3.34 | $175460.22 |
| 2026-09-18 | NGUYEN, TUAN | Chief Financial Officer | M | 265,625 | — | — |
| 2026-09-18 | NGUYEN, TUAN | Chief Financial Officer | M | 27,475 | — | — |
| 2026-09-18 | NGUYEN, TUAN | Chief Financial Officer | M | 265,625 | $3.49 | $927031.25 |
| 2026-09-18 | NGUYEN, TUAN | Chief Financial Officer | F | 206,637 | $5.07 | $1.05M |
| 2026-09-18 | NGUYEN, TUAN | Chief Financial Officer | M | 27,475 | $4.39 | $120615.25 |
| 2026-09-18 | BEARDSLEY, ROBERT A | Director | M | 78,800 | — | — |
| 2026-09-18 | BEARDSLEY, ROBERT A | Director | M | 52,533 | — | — |
| 2026-09-18 | BEARDSLEY, ROBERT A | Director | F | 99,057 | $5.07 | $502218.99 |
| 2026-09-18 | BEARDSLEY, ROBERT A | Director | M | 78,800 | $4.24 | $334112.00 |
| 2026-09-18 | BEARDSLEY, ROBERT A | Director | M | 52,533 | $3.20 | $168105.60 |
| 2026-09-18 | ANDROSKI, LINDSAY | Director, President and CEO | M | 116,408 | — | — |
| 2026-09-18 | ANDROSKI, LINDSAY | Director, President and CEO | M | 10,456 | — | — |
| 2026-09-18 | ANDROSKI, LINDSAY | Director, President and CEO | M | 116,408 | $3.20 | $372505.60 |
| 2026-09-18 | ANDROSKI, LINDSAY | Director, President and CEO | F | 82,527 | $5.07 | $418411.89 |
| 2026-09-18 | ANDROSKI, LINDSAY | Director, President and CEO | M | 10,456 | $4.39 | $45901.84 |
| 2026-06-08 | SAWHNEY, ROGER | Director | Buy | 78,800 | — | — |
| 2026-06-08 | BEARDSLEY, ROBERT A | Director | Buy | 78,800 | — | — |
| 2026-02-02 | NGUYEN, TUAN | Chief Financial Officer | Buy | 188,400 | — | — |
| 2026-02-02 | NGUYEN, TUAN | Chief Financial Officer | Buy | 73,500 | — | — |
| 2026-02-02 | ANDROSKI, LINDSAY | Director, President and CEO | Buy | 71,700 | — | — |
| 2026-02-02 | ANDROSKI, LINDSAY | Director, President and CEO | Buy | 28,000 | — | — |
| 2025-08-04 | SAWHNEY, ROGER | Director | Buy | 157,600 | — | — |
| 2025-03-31 | NGUYEN, TUAN | Chief Financial Officer | Buy | 750,000 | — | — |
| 2025-03-18 | HASIJA, ANUJ | Director | Buy | 157,600 | — | — |
| 2025-03-18 | BEARDSLEY, ROBERT A | Director | Buy | 157,600 | — | — |
| 2025-03-18 | ANDROSKI, LINDSAY | Director, President and CEO | Buy | 310,422 | — | — |
| 2025-02-14 | SIMS, KAREN | Chief Medical Officer | Buy | 200,300 | — | — |
| 2025-02-14 | SIMS, KAREN | Chief Medical Officer | Buy | 49,300 | — | — |
| 2025-02-14 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Buy | 220,300 | — | — |
| 2025-02-14 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Buy | 54,300 | — | — |
| 2025-02-14 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Buy | 718,800 | — | — |
| 2025-02-14 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Buy | 177,000 | — | — |
| 2025-02-14 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 365,800 | — | — |
| 2025-02-14 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 90,100 | — | — |
| 2025-02-04 | SIMS, KAREN | Chief Medical Officer | Sale | 19,348 | $3.28 | $63519.48 |
| 2025-02-04 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Sale | 11,333 | $3.28 | $37206.24 |
| 2025-02-04 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Sale | 23,790 | $3.28 | $78102.57 |
| 2025-02-04 | HASTINGS, DAVID C | Chief Financial Officer | Sale | 22,183 | $3.28 | $72826.79 |
| 2024-08-14 | MANCHESTER, KEITH S | Director | Sale | 54,915 | — | — |
| 2024-08-14 | MANCHESTER, KEITH S | Director | Buy | 54,915 | $0.56 | $30752.40 |
| 2024-08-14 | MANCHESTER, KEITH S | Director | Sale | 8,846 | $3.69 | $32637.32 |
| 2024-05-23 | TORTI, FRANK | Director | Buy | 67,000 | — | — |
| 2024-05-23 | REWOLINSKI, MELISSA | Director | Buy | 67,000 | — | — |
| 2024-05-23 | MEYERS, JAMES R | Director | Buy | 67,000 | — | — |
| 2024-05-23 | MANCHESTER, KEITH S | Director | Buy | 67,000 | — | — |
| 2024-05-23 | HENRIQUES, RICHARD C JR | Director | Buy | 67,000 | — | — |
| 2024-05-23 | BURGESS, DANIEL D | Director | Buy | 67,000 | — | — |
| 2024-02-02 | SOFIA, MICHAEL J. | Chief Scientific Officer | Sale | 9,982 | $2.31 | $23083.38 |
| 2024-02-02 | SIMS, KAREN | Chief Medical Officer | Sale | 4,358 | $2.31 | $10077.88 |
| 2024-02-02 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Sale | 10,164 | $2.31 | $23504.25 |
| 2024-02-02 | HASTINGS, DAVID C | Chief Financial Officer | Sale | 9,593 | $2.31 | $22183.81 |
| 2024-02-01 | SOFIA, MICHAEL J. | Chief Scientific Officer | Buy | 437,800 | — | — |
| 2024-02-01 | SOFIA, MICHAEL J. | Chief Scientific Officer | Buy | 109,500 | — | — |
| 2024-02-01 | SIMS, KAREN | Chief Medical Officer | Buy | 403,900 | — | — |
| 2024-02-01 | SIMS, KAREN | Chief Medical Officer | Buy | 101,000 | — | — |
| 2024-02-01 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Buy | 380,500 | — | — |
| 2024-02-01 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Buy | 95,100 | — | — |
| 2024-02-01 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Buy | 495,100 | — | — |
| 2024-02-01 | MCELHAUGH, MICHAEL J. | Director, Interim President & CEO | Buy | 123,800 | — | — |
| 2024-02-01 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 450,000 | — | — |
| 2024-02-01 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 112,500 | — | — |
| 2023-07-12 | REWOLINSKI, MELISSA | Director | Buy | 110,000 | — | — |
| 2023-07-10 | SIMS, KAREN | Chief Medical Officer | Buy | 153,640 | — | — |
| 2023-07-10 | NAFTZGER, J. CHRISTOPHER | General Counsel and CCO | Buy | 500,000 | — | — |
| 2023-05-24 | TORTI, FRANK | Director | Buy | 55,000 | — | — |
| 2023-05-24 | MEYERS, JAMES R | Director | Buy | 55,000 | — | — |
| 2023-05-24 | MANCHESTER, KEITH S | Director | Buy | 55,000 | — | — |
| 2023-05-24 | HENRIQUES, RICHARD C JR | Director | Buy | 55,000 | — | — |
| 2023-05-24 | BURGESS, DANIEL D | Director | Buy | 55,000 | — | — |
| 2023-02-01 | SOFIA, MICHAEL J. | Chief Scientific Officer | Buy | 328,700 | — | — |
| 2023-02-01 | SOFIA, MICHAEL J. | Chief Scientific Officer | Buy | 82,200 | — | — |
| 2023-02-01 | MCELHAUGH, MICHAEL J. | Chief Business Officer | Buy | 334,700 | — | — |
| 2023-02-01 | MCELHAUGH, MICHAEL J. | Chief Business Officer | Buy | 83,700 | — | — |
| 2023-02-01 | HOWARD, ELIZABETH | EVP, GC, Compliance | Buy | 278,700 | — | — |
| 2023-02-01 | HOWARD, ELIZABETH | EVP, GC, Compliance | Buy | 69,700 | — | — |
| 2023-02-01 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 316,000 | — | — |
| 2023-02-01 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 79,000 | — | — |
| 2023-02-01 | COLLIER, WILLIAM H. | Director, President and CEO | Buy | 866,000 | — | — |
| 2023-02-01 | COLLIER, WILLIAM H. | Director, President and CEO | Buy | 216,500 | — | — |
| 2022-05-25 | TRAN, TRAM | Director | Buy | 41,000 | — | — |
| 2022-05-25 | TORTI, FRANK | Director | Buy | 41,000 | — | — |
| 2022-05-25 | MEYERS, JAMES R | Director | Buy | 41,000 | — | — |
| 2022-05-25 | MANCHESTER, KEITH S | Director | Buy | 41,000 | — | — |
| 2022-05-25 | HENRIQUES, RICHARD C JR | Director | Buy | 41,000 | — | — |
| 2022-05-25 | BURGESS, DANIEL D | Director | Buy | 41,000 | — | — |
| 2022-01-20 | SOFIA, MICHAEL J. | Chief Scientific Officer | Buy | 285,000 | $2.81 | $800850.00 |
| 2022-01-20 | PICCHIO, GASTON | Chief Development Officer | Buy | 256,500 | $2.81 | $720765.00 |
| 2022-01-20 | MCELHAUGH, MICHAEL J. | Chief Business Officer | Buy | 325,850 | $2.81 | $915638.50 |
| 2022-01-20 | HOWARD, ELIZABETH | Chief Compliance Officer | Buy | 237,500 | $2.81 | $667375.00 |
| 2022-01-20 | HASTINGS, DAVID C | Chief Financial Officer | Buy | 285,000 | $2.81 | $800850.00 |
Frequently asked questions
Are ABUS insiders buying or selling?
Over the transactions on record, ABUS insiders have been net buyers, with about $45.74M in stock sold across 15 sales, against 6 open-market purchases.
Does insider selling at ABUS mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which ABUS insiders are selling the most?
Recent selling is concentrated in a few names. ROIVANT, SCIENCES LTD. accounts for the largest share on record, with about $44.84M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.